Women of childbearing potential/contraception in females: Women of childbearing potential should use effective contraception during treatment.
Pregnancy: For ranibizumab no clinical data on exposed pregnancies are available. Studies in cynomolgus monkeys do not indicate direct or indirect harmful effects with respect to pregnancy or embryonal/foetal development (see Pharmacology: Toxicology: Preclinical safety data under Actions). The systemic exposure to ranibizumab is low after ocular administration, but due to its mechanism of action, ranibizumab must be regarded as potentially teratogenic and embryo-/foetotoxic. Therefore, ranibizumab should not be used during pregnancy unless the expected benefit outweighs the potential risk to the foetus. For women who wish to become pregnant and have been treated with ranibizumab, it is recommended to wait at least 3 months after the last dose of ranibizumab before conceiving a child.
Breast-feeding: It is unknown whether Lucentis is excreted in human milk. Breast-feeding is not recommended during the use of Lucentis.
Fertility: There are no data available on fertility.